top of page


Post ASCO 2018

Barely 8 weeks after visiting the city for the AACR 2018 annual meeting, MedSIR returned to Chicago for ASCO 2018! McCormick Place is the largest convention center in North America, but at MedSIR we feel we already know all its nooks and crannies!

If this year’s AACR meeting was exciting, ASCO didn’t lag behind! The results of many new trials involving immune checkpoint inhibitors were presented, indicating that immunotherapy is the queen at the ball of current oncology. Pembrolizumab, for example, continued to show impressive results in lung cancer patients, including those at an early stage of the disease.

But not everything was related to immunotherapy! A new targeted therapy against PIK3CA (taselesib) was shown to slow the growth of advanced breast cancers, and innovative ways of using chemotherapy were shown to significantly extend the lives of patients with pancreatic cancer, one of the most deadly tumours.

One of the highlights of the Congress was the presentation of the results of the study TAILORx, which used Oncotype DX gene expression assay to prove that many women with early breast cancer can avoid chemotherapy without fear of worsening their prognosis. The findings will be a game-changer in breast cancer care, since from now on the use of chemotherapy can be directed only to the patients that will actually benefit from it.

But more important than the number of steps we walked going from one results presentation to another is the number of hands we shook with existing partners and potential new clients! We immediately got to work in building exciting relationships with both established companies and bold new players, in order to get the most out of the possibilities that all these advances offer to cancer patients worldwide! Feel free to contact us if you have an idea about the matter!

It was a great, successful, exhausting meeting, and therefore we can’t wait for ASCO 2019! See you all back next year in Sweet Home Chicago!




bottom of page